{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:23:26Z","timestamp":1784928206829,"version":"3.55.0"},"reference-count":8,"publisher":"Informa Healthcare","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1517\/13543784.13.4.435","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T21:27:20Z","timestamp":1115242040000},"page":"435-445","source":"Crossref","is-referenced-by-count":9,"title":["American Heart Association Scientific Sessions"],"prefix":"10.1517","volume":"13","author":[{"given":"Bernhard R","family":"Winkelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2005,3,2]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.5.1099"},{"key":"CIT0002","first-page":"3032","volume":"102","author":"THE","year":"2000","journal-title":"For the Guard During Ischemia Against Necrosis (GUARDIAN) investigators. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations \u2014 main results of the GUARDIAN trial. Circulation"},{"key":"CIT0003","first-page":"1644","volume":"38","author":"ZEYMER U","year":"2001","journal-title":"The Na\u00b1\/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction - results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) Trial. J. Am. Coll. Cardiol"},{"key":"CIT0004","first-page":"1893","volume":"349","author":"PFEFFER MA McMURRAY","year":"2003","journal-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. I Med."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09895-1"},{"key":"CIT0006","first-page":"1667","volume":"345","author":"COHN JN","year":"2001","journal-title":"A randomized trial of the angiotensin-receptor inhibitor valsartan in chronic heart failure. N Engl. Med."},{"key":"CIT0007","first-page":"759","volume":"362","author":"McMURRAY JJV, OSTERGREN J, SWEDBERG K et al.","year":"2003","journal-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet"},{"key":"CIT0009","first-page":"1071","volume":"291","author":"NISSEN SE","year":"2004","journal-title":"Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.13.4.435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T13:02:56Z","timestamp":1481634176000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.13.4.435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,3,2]]},"published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1517\/13543784.13.4.435"],"URL":"https:\/\/doi.org\/10.1517\/13543784.13.4.435","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}